|

Efficacy and Safety of Photodynamic Therapy for CIN3

RECRUITINGN/ASponsored by Peking University Third Hospital
Actively Recruiting
PhaseN/A
SponsorPeking University Third Hospital
Started2024-01-01
Est. completion2028-12-31
Eligibility
Age18 Years – 65 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07009327

Summary

To investigate the efficacy and safety of photodynamic therapy (20% 5-amino-ketovalerate 630nm red light) in the treatment of cervical intraepithelial neoplasia 3(CIN 3)in women in the real world

Eligibility

Age: 18 Years – 65 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* CIN3, photodynamic therapy was required,
* type 1 2 transformation area, colposcopy was sufficient
* the lesion boundary was completely visible
* The ECC did not indicate high-grade lesions

Exclusion Criteria:

* coexistence or suspicion of cancer;
* TCT HSIL
* involving glands
* Porphyria patients, or suspected allergic to red and blue light.
* severe medical comorbidities；

Conditions2

CancerPrecancerous Cervical Lesion

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.